Table 1 Summary of the included studies
First author | Publication year | Data source | Type of study | number of cases (experimental group/control group) | Total number of cases (n) | Method of administration |
|---|---|---|---|---|---|---|
Wu SR [11] | 2020 | China | RCT | 45/45 | 90 | Intranasal |
Chu L [12] | 2021 | China | RCT | 70/70 | 140 | Intranasal |
Chen JY [14] | 2013 | China | RCT | 28/28 | 56 | Intravenous |
Ye WD [15] | 2014 | China | RCT | 30/30 | 60 | Intravenous |
Kim J [16] | 2014 | Korea | RCT | 47/47 | 94 | Intravenous |
Abdelaziz HMM [17] | 2016 | Egypt | RCT | 35/35 | 70 | Intranasal |
Song IA [18] | 2016 | Korea | RCT | 25/25 | 50 | Intravenous |
Abdel-Rahman KA [19] | 2018 | Egypt | RCT | 30/30 | 60 | Intravenous |
Dai BZ [20] | 2020 | China | RCT | 48/48 | 96 | Intravenous |
Li S [21] | 2020 | China | RCT | 42/42 | 84 | Intravenous |
Yao Y [22] | 2020 | China | RCT | 32/32 | 64 | Intranasal |
Elghamry MR [23] | 2021 | Egypt | RCT | 35/35 | 70 | Intravenous |
Oriby ME [24] | 2021 | Qatar | RCT | 42/42 | 84 | Intravenous |